Becton Dickinson And Company (BDX) closed at $198.60 on November 2, 2026, up 0.4% from the previous close, on volume of 1,595,597 shares (30-day average 1,498,069).
Data as of November 2, 2026.
PRNewswire (Wed, 28-Oct 6:50 AM ET)
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
PRNewswire (Thu, 8-Oct 4:16 PM ET)
BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
PRNewswire (Thu, 8-Oct 6:50 AM ET)
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
PRNewswire (Wed, 7-Oct 8:01 AM ET)
BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
PRNewswire (Tue, 6-Oct 9:01 AM ET)
BD Appoints Ferass Abuzaina as Worldwide President of Surgery
PRNewswire (Tue, 6-Oct 6:50 AM ET)
PRNewswire (Tue, 6-Oct 6:36 AM ET)
BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
PRNewswire (Tue, 29-Sep 9:01 AM ET)
Arthur Hu to Join BD as Chief Information and Digital Officer
PRNewswire (Mon, 21-Sep 4:30 PM ET)
BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
PRNewswire (Mon, 14-Sep 6:50 AM ET)
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Becton Dickinson And Company trades on the NYSE stock market under the symbol BDX.
As of November 2, 2026, BDX stock price climbed to $198.60 with 1,595,597 million shares trading.
BDX has a beta of 0.06, meaning it tends to be less sensitive to market movements. BDX has a correlation of 0.00 to the broad based SPY ETF.
BDX has a market cap of $56.50 billion. This is considered a Large Cap stock.
Last quarter Becton Dickinson And Company reported $5 billion in Revenue and $3.23 earnings per share. This beat revenue expectation by $96 million and exceeded earnings estimates by $.10.
In the last 3 years, BDX traded as high as $259.92 and as low as $140.11.
The top ETF exchange traded funds that BDX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BDX has outperformed the market in the last year with a price return of +37.8% while the SPY ETF gained +11.7%. BDX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.7% and +3.6%, respectively, while the SPY returned +1.7% and -1.5%, respectively.
BDX support price is $194.71 and resistance is $201.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDX shares will trade within this expected range on the day.
